<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973891</url>
  </required_header>
  <id_info>
    <org_study_id>777</org_study_id>
    <nct_id>NCT04973891</nct_id>
  </id_info>
  <brief_title>CANA/Met in Non-diabetic Women With PCOS</brief_title>
  <official_title>Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS), which is associated with hyperinsulinaemia,&#xD;
      hyperandrogenaemia, impaired glucose metabolism and aberrant adipokines production from the&#xD;
      adipose tissue, is a heterogeneous reproductive and endocrine disorder.Currently, metformin,&#xD;
      a classical and common insulin sensitizer that can reduce both hyperinsulinemia and&#xD;
      hyperandrogenemia, is widely used for patients with PCOS. SGLT-2 inhibitor, a novel&#xD;
      glucose-lowering medication, have been shown to have positive effects on reducing body&#xD;
      weight, blood pressure and cardiovascular events in individuals with diabetes mellitus.&#xD;
      However, evidences related to its management in non-diabetic PCOS women are limited. Hence,&#xD;
      we want to give canangliflozin combined with metformin to women with PCOS to see its effect&#xD;
      on insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">June 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in body mass index (BMI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total testosterone</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in total testosterone (TT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in androstenedione (AND)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone sulfate</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in dehydroepiandrosterone sulfate (DHEA-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone-binding globulin</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in sex hormone-binding globulin (SHBG)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental: Canagliflozin/metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with canagliflozin combined with metformin for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with metformin for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin combined with metformin</intervention_name>
    <description>Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.&#xD;
Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.</description>
    <arm_group_label>Active Comparator: Metformin group</arm_group_label>
    <arm_group_label>Experimental: Canagliflozin/metformin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female aged 18- 45 years old;&#xD;
&#xD;
          2. Diagnosed criteria meet the Rotterdam criteria (2003);&#xD;
&#xD;
          3. Insulin Resistance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or have a pregnancy plan within six months;&#xD;
&#xD;
          2. Confirmed diagnosis of diabetes.&#xD;
&#xD;
          3. Congenital adrenocortical hyperplasia;&#xD;
&#xD;
          4. Hyperprolactinemia;&#xD;
&#xD;
          5. Hyperthyroidism or hypothyroidism;&#xD;
&#xD;
          6. Combined with liver or kidney diseases;&#xD;
&#xD;
          7. Abnormal liver function (â‰¥ 3 times of the upper limit of normal range);&#xD;
&#xD;
          8. Abnormal renal function (GFR&lt;60ml/min/1.73m2);&#xD;
&#xD;
          9. Adrenal or ovarian tumors secreting androgens;&#xD;
&#xD;
         10. Used metformin, glucagon-like peptide-1 receptor agonists, pioglitazone and&#xD;
             contraceptives in the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Bing He</investigator_full_name>
    <investigator_title>Professor Bing He</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

